CULPRIT-SHOCK

We asked CULPRIT-SHOCK Work-package leaders about their research, their involvement within the project and their future visions. See and read what the Experts had to say.

Interview with Gilbert W.M. Wijntjens, Academic Medical Center Amsterdam

WP5 – "Microcirculation"

 

What is your teams’ involvement in the project?


Under supervision of Prof. Dr. Jan J. Piek and Dr. Georg Fürnau, I’m the lead investigator of the microcirculation sub-study of the CULPRIT‑SHOCK trial.


What in your opinion is the innovative capacity of the CULPRIT‑SHOCK trial and its results?


The CULPRIT-SHOCK study undisputedly influenced therapeutic approaches towards cardiogenic shock complicated acute myocardial infarction.

 

What needs to happen in your view in cardiogenic shock to say, “a dream has come true”?


A substantial reduction in early-mortality rates for patients with acute myocardial infarction complicated by cardiogenic shock, as well as, significant improvement in quality of life after cardiogenic shock.


undefineddownload this interview

Interview with Dr. Steffen Schneider, Institut für Herzinfarktforschung, Ludwigshafen

WP6 - "Data management and statistical analysis" 

 

 

What is your teams’ involvement in the project?

The involvement of IHF team is as follows:

·         Development of statistical concept of CULPRIT shock

·         Electronic CRF and trial database

·         Guidance of sites (initiation visits, monitoring, and close-out visits)

·         Statistical analyses

·         Support of publications and presentations

·         Writing of study reports

 

What in your opinion is the innovative capacity of the CULPRIT-SHOCK trial and its results?

The CULPRIT shock trial and it results shows the importance of funding programs for clinical trials. Independent from economic interests, cardiologic research must be possible.

 

What needs to happen in your view in cardiogenic shock to say, “a dream has come true”? 

In my point of view, it will be important that we use the established scientific cooperation with sites in different countries for further research in the field of cardiogenic shock. That is my “dream”.


undefinedDownload this interview

Interview with Prof. Steffen Desch, Universitätsklinikum Schleswig-Holstein, Lübeck

WP8 – "Predictive prognostic model and risk score"

 

What is your teams’ involvement in the project?

My team has been involved in CULPRIT-SHOCK from the very start of shaping the project’s main ideas and concepts to drafting the necessary documents, obtaining financial support, organizing practical execution and finally presenting the game-changing results.

 

What in your opinion is the innovative capacity of the CULPRIT-SHOCK trial and its results?

CULPRIT-SHOCK gave a very clear answer to a specific clinical question. This will without doubt change the way patients in infarct-related cardiogenic shock are being treated. Apart from the stunning results, the innovation of CULPRIT-SHOCK is in the proof that such studies in extremely sick and complex patients can be done. It is an open invitation to researchers to address other unresolved questions in such populations.

 

Which parameters help to identify particular patients at risk in cardiogenic shock? Do these patients have a benefit from a more aggressive treatment such as mechanical circulatory support?

Prior evidence has already shed some light on which patients are at the highest risk of death. Old age, deranged glucose metabolism, altered renal function, unsuccessful coronary intervention or poor overall tissue perfusion all seem to predict adverse outcome. It is one of the key questions if these extreme-risk patients might benefit from advanced therapies like mechanical circulatory support, something that needs to be addressed in future studies.

 

What needs to happen in your view in cardiogenic shock to say, “a dream has come true”?

Although treatment of cardiogenic shock has made major improvements in recent years, there is still a long way ahead of us. Roughly 1 out 2 patient dies in the acute phase. If we can arrive at a further significant mortality reduction within the next 10 or 15 years, a dream would have come true.

 



undefinedDownload this interview

Home
Menu
Search
Top

Newsletter Subscription